Table 1 Comparison of tryptophan levels in HIV/AIDS patients of this study and that of developed countries
| Â | A | B | C | D | p value |
|---|---|---|---|---|---|
Controls | Total group | ART—naïve | ART | ||
Present study (gc) | 43.6 (n = 60) | 24.4 (n = 105) | 22.0 (n = 30) | 25.1 (n = 75) (71.0% on ART) | <0.001 (A–B) <0.001 (A–C) <0.001 (A–D) 0.03 (C–D) |
Developed countries: | |||||
Werner et al. 1988 [10] (h) | 91.0 | 44.8 (n = 11) | - | - | <0.0001 (A–C) |
Larsson et al. 1989 [11] (h) | 39.7 (n = 14) | 28.4 (n = 24) | - | - | <0.05 (A–B) |
Fuchs et al. 1990 [12] (h) | 91.1 (n = 11) | 48.8 dementia 70.5 | - | - | <0.05 (A–B) <0.01 (A–B) |
Fuchs et al. 1990 [9] (h) | 39.7 | 29.8 (n = 22) | - | - | - |
Fuchs et al. 1991 [13] (h) | 91.0 | 57.0 (n = 42) | (62 % naïve) | (38 % on ART) | <0.01 (A–B) |
Heyes et al. 1992 [14] (h) | 70.9 (n = 20) | 40.2 (n = 107) | - | - | <0.0001 (A–B) |
Gisselen et al. 1994 [15] (h) | - | 29.4 (n = 14) | 29.4 (pre-ART) | 36.2 (post-ART) | <0.01 (C–D) |
Hortin et al. 1994 [16] (fl) | 46 (n = 20) | 22 (n = 20) | - | (85 % on ART) | <0.001 (A–B) |
Laurichesse et al. 1998 [17] (fl) | 59 (n = 8) | 51 (n = 7) | - | - | <0.05 (A–B) |
Huengsberg et al. 1998 [18] (h) | 56.3 (n = 72) | 50.1 (n = 82) | - | - | <0.01 (A–B) |
Look et al. 2000 [19] (gc) | 52.6 (n = 55) | 44.6 (n = 17) 37.4 (n = 7) AIDS | 44.6 (pre-ART) | 53.0 (post-ART) | 0.14 (A–B) 0.009 (A–B) 0.039 (C–D) |
Murray et al. 2001 [20] (h) | 49.3 | 69.2 (post niacin treatment) | - | - | - |
Zangerle et al. 2002 [8] (h) | 65.8 (n = 40) | 44.1 (n = 45) | 44.1 (pre-ART) | 53.2 (post-ART) | <0.001 (A–B) <0.001 (A–D) 0.001 (C–D) |
Schroeksnadel et al. 2008 [6] (h) | - | 51.4 (n = 152) | - | (70 % on ART) | - |